Identical to NBI-1065845 tablets without active drug
Sponsors
Neurocrine Biosciences Inc.
Conditions
Major Depressive Disorder
Phase 3
NBI-1065845-MDD3024: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
RecruitingCTIS2024-519418-29-00
Start: 2025-09-19Target: 82Updated: 2025-11-14
NBI-1065845-MDD3025: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
RecruitingCTIS2024-519420-25-00
Start: 2025-10-22Target: 93Updated: 2026-01-16
NBI-1065845-MDD3026: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
RecruitingCTIS2024-519421-37-00
Start: 2025-08-28Target: 55Updated: 2025-12-22
NBI-1065845-MDD3027: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI 1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
RecruitingCTIS2025-520541-72-00
Start: 2025-10-22Target: 158Updated: 2025-12-22